John M. Kane, MD

Northwell, New Hyde Park, New York (Kane, Robinson); Feinstein Institutes for Medical Research, Northwell Health, Manhasset New York; Department of Psychiatry, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York

  • 123Articles
  • 699.6KReads
  • 1996–2026Active
  • 271Collaborators
  • 4KCitations

About

John M. Kane, MD, is affiliated with The Zucker Hillside Hospital, Northwell Health, the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and the Feinstein Institute for Medical Research. His extensive publication record since 1996 includes over 120 articles focusing on schizophrenia, schizoaffective disorders, bipolar disorder, mood disorders, child and adolescent psychiatry, neurology, movement disorders, and patient care. Kane's work addresses topics such as antipsychotic treatment strategies, long-acting injectable agents, clinical tools for tardive dyskinesia assessment, and optimizing medication adherence. He has frequently collaborated with Christoph U. Correll, Peter Manu, Stephen R. Marder, Leslie Citrome, and Nina R. Schooler.

Publications

JCP
Long-Acting Injectable Antipsychotics and Clozapine in Coordinated Specialty Care: Data From EPINET
Original Research

Long-Acting Injectable Antipsychotics and Clozapine in Coordinated Specialty Care: Data From EPINET

September 14, 2026

Data from the EPINET project reveal wide variation in the prescription of LAIs and clozapine across first-episode specialty care clinics.
, , , et al
JCP
Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic?
ASCP Corner

Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic?

January 26, 2026

This article will familiarize US clinicians with amisulpride’s history and data, and the rationale behind development of LB-102, an N-methylated analogue of amisulpride.
,
JCP
LAI Implementation After Schizophrenia Diagnosis
Original Research

LAI Implementation After Schizophrenia Diagnosis

April 19, 2023

Although long-acting injectable antipsychotic agents (LAIs) are effective in preventing relapse, their use in first-episode schizophrenia was low, and LAIs were rarely the first therapy for early-phase schizophrenia.
, , , et al
JCP
Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness
Original Research

Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness

March 22, 2023

In patients with early-phase schizophrenia or bipolar disorder, combination olanzapine and samidorphan resulted in less weight gain at week 12 than olanzapine alone. Antipsychotic efficacy was similar between the...
, , , et al
JCP
Predictors for Initiation of LAIs in Individuals With Early-Phase Schizophrenia
Original Research

Predictors for Initiation of LAIs in Individuals With Early-Phase Schizophrenia

February 13, 2023

Initiation of LAIs was predicted by greater switching of oral antipsychotics and more ED visits. LAIs are often used to respond to relapse rather than prevent it.
, , , et al
JCP
Impact-TD Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia
Consensus Statement

Impact-TD Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia

November 28, 2022

This easy-to-use scale developed by 7 experts measures the impact of TD on patients’ daily functioning.
, , , et al
JCP
Reasons for Switching Antipsychotic Treatments
Original Research

Reasons for Switching Antipsychotic Treatments

September 5, 2022

Based on prescription records and prescriber notes, almost half of antipsychotic switches were due to side effects, and women were especially likely to be switched due to intolerability or...
, , , et al
JCP
ASCP Corner

How to Make an Effective Offer of Clozapine

November 30, 2021

This ASCP Corner article discusses how to identify treatment-resistant patients who would benefit from clozapine and then offers tips on how to start the treatment conversation with these patients.
,
JCP
Academic Highlights

Improving Outcomes in Schizophrenia

May 4, 2021

What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical...
,
JCP
Educational Activity

Lessening the Side Effect Burden in Schizophrenia

March 23, 2021

Patients may be more willing to accept some adverse effects than others. Dr Kane offers advice on addressing side effects that prevent patients from maintaining their medication adherence.
JCP
Review Article

Outcomes of NMS With Depot Versus Oral Antipsychotics

November 24, 2020

Is the advantage of longer-term medication release with long-acting injectable antipsychotics offset by an increased risk of more prolonged and severe neuroleptic malignant syndrome? This systematic review and pooled...
, , , et al
JCP
Letter to the Editor

Drs Kane and Correll Reply

June 16, 2020

Drs Kane and Correll reply to the letter "Depression as a Factor in Nonadherence in Schizophrenia" by Hirakawa and Ishii.
,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe